Global Non-melanoma Skin Cancer Market 2014-2018
Published: May 2014 No. of Pages: 119
Mail us: sales@reportsandintelligence.com Detailed report at: http://www.reportsandintelligence.com/global-nonmelanoma-skin-cancer-2014-2018-market Website: http://www.reportsandintelligence.com
About Diabetic Neuropathy Diabetes is usually associated About Non-melanoma Skin Cancer Non-melanoma skin cancer is one of the most common types of cancer in the world. It develops in the upper layers of the skin, but not in melanocytes. There are two types of non-melanoma skin cancer: BCC, which starts in the basal cells, and SCC, which starts in the squamous cells. BCC usually develops in the areas such as the head and neck, whereas SCC starts in the face, ears, neck, lips, and backs of the hands. These can also grow in wounds or chronic skin sores. Nonmelanoma skin cancer is caused by unprotected and excessive exposure to UV radiation. It affects men more than women. It can be cured effectively if it is detected early. Treatment for non-melanoma skin cancer includes surgery, laser therapy, cryotherapy, creams, radiotherapy, chemotherapy, and PDT. TechNavio's analysts forecast the Global Non-melanoma Skin Cancer market to grow at a CAGR of 27.93 percent over the period 2013-2018. Covered in this Report This report covers the present scenario and the growth prospects of the Global Non-melanoma Skin Cancer market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the following segments: • Chemotherapy, which includes drugs used in the treatment of SCC, BCC, and actinic keratosis • Non-invasive Treatments, which include PDT, radiotherapy, cryotherapy, and laser therapy TechNavio's report, the Global Non-melanoma Skin Cancer Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and, the EMEA and the APAC region; and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Vendors • Elekta AB • F. Hoffmann-la Roche Ltd. • iCAD Inc. • Meda AB • Valeant Pharmaceuticals Inc. • Varian Medical Systems Inc. Other Prominent Vendors • Aqua Pharmaceuticals LLC • Almirall SA • Biofrontera AG • Boehringer Ingelheim GmbH • Bristol Myers Squibb Co. • Cannabis Science Inc. • Cellceutix Corp. • Eli Lilly and Co. • Galderma SA • GENEXTRA SpA • IRX Therapeutics Inc. • LEO Pharma A/S • Merck & Co. Inc. • Moberg Pharma AB • Mylan Pharmaceutical Inc. • Novartis International AG • Oncothyreon Inc. • Sun Pharma Industries Ltd. Market Driver • Increasing Incidence of Non-melanoma Skin Cancer • For a full, detailed list, view our report. Market Challenge • Availability of Alternative Treatments • For a full, detailed list, view our report.
Market Trend • Emergence of Combination Therapies • For a full, detailed list, view our report. Key Questions Answered in this Report • What will the market size be in 2018 and what will the growth rate be? • What are the key market trends? • What is driving this market? • What are the challenges to market growth? • Who are the key vendors in this market space? • What are the market opportunities and threats faced by the key vendors? • What are the strengths and weaknesses of the key vendors? You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report. More Information about Global Non-melanoma Skin Cancer Market
Detailed report at: http://www.reportsandintelligence.com/globalnon-melanoma-skin-cancer-2014-2018-market
Table of Content 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 03.1 Market Overview 03.2 Product Offerings 04. Market Research Methodology 04.1 Market Research Process 04.2 Research Methodology 05. Introduction 06. Market Landscape 06.1 Market Overview 06.2 Market Size and Forecast 06.3 Global Non-melanoma Skin Cancer Drugs Market
06.3.1 Market Size and Forecast 06.4 Global Actinic Keratosis Drugs Market 06.4.1 Market Overview 06.4.2 Market Size and Forecast 06.5 Top Selling Drugs for the Treatment of BCC, SCC, and Actinic Keratosis 06.6 Five Forces Analysis 07. Market Segmentation by Type 07.1 Global Non-melanoma Skin Cancer Drugs Market by Type 07.1.1 BCC 07.1.2 SCC 07.2 Global BCC Drugs Market 07.2.1 Market Size and Forecast 07.3 Global SCC Drugs Market 07.3.1 Market Size and Forecast 08. Pipeline Analysis 09. Geographical Segmentation 09.1 Global Non-melanoma Skin Cancer Market by Geographical Segmentation 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Trends and their Impact 17. Vendor Landscape 17.1 Market Share Analysis 2013 17.2 Global Actinic Keratosis Drugs Market 17.3 Other Prominent Vendors 18. Non-invasive Treatment Market 18.1 Global Non-melanoma Skin Cancer Radiotherapy Market 18.1.1 Market Size and Forecast
18.2 Global Non-melanoma Skin Cancer Cryotherapy Market 18.2.1 Market Size and Forecast 18.3 Global Non-melanoma Skin Cancer PDT Market 18.3.1 Market Size and Forecast 18.4 Global Non-melanoma Skin Cancer Laser Therapy Market 18.4.1 Market Size and Forecast 18.5 Vendor Share 18.5.1 Global Non-melanoma Skin Cancer Radiotherapy Equipment Market 18.5.2 Global Non-melanoma Skin Cancer Cryotherapy Equipment Market 18.5.3 Global Non-melanoma Skin Cancer PDT Equipment Market 18.5.4 Global Non-melanoma Skin Cancer Laser Equipment Market 19. Key Vendor Analysis 19.1 Elekta AB 19.1.1 Key Facts 19.1.2 Business Description 19.1.3 Product Categorization 19.1.4 Revenue by Product Offerings 19.1.5 Revenue Comparison by Geographical Segmentation 2012 and 2013 19.1.6 Revenue Comparison by Geographical Segmentation 19.1.7 Business Strategy 19.1.8 Key Developments 19.1.9 SWOT Analysis 19.1.10 Strengths 19.1.11 Weaknesses 19.1.12 Opportunities 19.1.13 Threats 19.2 F. Hoffmann-La Roche Ltd. 19.2.1 Key Facts 19.2.2 Business Description 19.2.3 Business Segmentation 19.2.4 Revenue by Business Segmentation
19.2.5 Geographical Sales Segmentation by Business Segments 19.2.6 Business Strategy 19.2.7 Key Information 19.2.8 SWOT Analysis 19.2.9 Strengths 19.2.10 Weaknesses 19.2.11 Opportunities 19.2.12 Threats 19.3 iCAD Inc. 19.3.1 Key Facts 19.3.2 Business Description 19.3.3 Business Segmentation 19.3.4 Revenue by Business Segmentation 19.3.5 Revenue Comparison by Business Segmentation 2012 and 2013 19.3.6 Revenue by Geographical Segmentation 19.3.7 Business Strategy 19.3.8 Key Developments 19.3.9 SWOT Analysis 19.3.10 Strengths 19.3.11 Weaknesses 19.3.12 Opportunities 19.3.13 Threats 19.4 Meda AB 19.4.1 Key Facts 19.4.2 Business Description 19.4.3 Product Segmentation 19.4.4 Revenue by Product Segmentation 19.4.5 Revenue Comparison by Product Segmentation 2012 and 2013 19.4.6 Revenue by Geographical Segmentation 19.4.7 Business Strategy 19.4.8 Key Developments
19.4.9 SWOT Analysis 19.4.10 Strengths 19.4.11 Weaknesses 19.4.12 Opportunities 19.4.13 Threats 19.5 Valeant Pharmaceuticals International Inc. 19.5.1 Key Facts 19.5.2 Business Description 19.5.3 Business Segmentation 19.5.4 Revenue Comparison by Business Segmentation 2011-2013 19.5.5 Revenue by Geographical Segmentation 19.5.6 Business Strategy 19.5.7 Key Developments 19.5.8 SWOT Analysis 19.5.9 Strengths 19.5.10 Weaknesses 19.5.11 Opportunities 19.5.12 Threats 19.6 Varian Medical Systems Inc. 19.6.1 Key Facts 19.6.2 Business Description 19.6.3 Business Segmentation 19.6.4 Revenue by Business Segmentation 19.6.5 Revenue Comparison by Business Segmentation 2013 and 2012 19.6.6 Revenue by Geographical Segmentation 19.6.7 Business Strategy 19.6.8 Key Developments 19.6.9 SWOT Analysis 19.6.10 Strengths 19.6.11 Weaknesses 19.6.12 Opportunities
19.6.13 Threats 20. Other Reports in this Series
Get detailed TOC at: http://www.reportsandintelligence.com/global-nonmelanoma-skin-cancer-2014-2018-market/table-of-contents
Contact Us: Cathy Viber 5933 NE Win Sivers Drive, #205, Portland, OR 97220 United States Direct: +1 (617) 674-4143 Toll Free: +1 (855) 711-1555 Fax: +1 (855) 550-5975 Email: sales@reportsandintelligence.com Web: http://www.reportsandintelligence.com/ Twitter: https://twitter.com/RNIntelligence